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Background: The pathogenesis of colorectal neoplasia is still unresolved but has been associated with alterations
in epithelial clearance of xenobiotics and metabolic waste products. The aim of this study was to functionally
characterize the transport of cyclic nucleotides in colonic biopsies from patients with and without colorectal
neoplasia.
Methods: Cyclic nucleotides were used as model substrates shared by some OATP- and ABC-transporters, which in
part are responsible for clearance of metabolites and xenobiotics from the colonic epithelium. On colonic biopsies
from patients with and without colorectal neoplasia, molecular transport was electrophysiologically registered in
Ussing-chamber set-ups, mRNA level of selected transporters was quantified by rt-PCR, and subcellular location of
transporters was determined by immunohistochemistry.
Results: Of four cyclic nucleotides, dibuturyl-cAMP induced the largest short circuit current in both patient groups.
The induced short circuit current was significantly lower in neoplasia-patients (p = 0.024). The observed altered
transport of dibuturyl-cAMP in neoplasia-patients could not be directly translated to an observed increased mRNA
expression of OATP4A1 and OATP2B1 in neoplasia patients. All other examined transporters were expressed to
similar extents in both patient groups.
Conclusions: OATP1C1, OATP4A1, OATP4C1 seem to be involved in the excretory system of human colon. ABCC4
is likely to be involved from an endoplasmic-Golgi complex and basolateral location in goblet cells. ABCC5 might
be directly involved in the turnover of intracellular cAMP at the basolateral membrane of columnar epithelial cells,
while OATP2B1 is indirectly related to the excretory system. Colorectal neoplasia is associated with lower transport
or sensitivity to cyclic nucleotides and increased expression of OATP2B1 and OATP4A1 transporters, known to
transport PGE2.
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Colorectal neoplasia (CRN) and colorectal cancer (CRC)
still pose major challenges concerning etiology, early
diagnosis, prognosis, and treatment. Deaths due to colo-
rectal cancer rank among the highest cancer related
mortalities [1]. Recently, epithelial transporter dysfunc-
tions of the colon have attracted attention in relation to* Correspondence: kkh@farma.ku.dk
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reproduction in any medium, provided the ordevelopment of CRN and CRC [2-4]. The colon has a
molecular excretory system build to excrete xenobiotics,
toxins and waste metabolites in parallel with excretory
systems found in kidney and liver [4]. Many molecular
transporters are conceived to take part in this excretory
paradigm of the colon. Several of these transporters are
also considered important for controlling the level of
intracellular signaling molecules [5,6]. Selective basolat-
eral and apical molecular transporters of normal colonic
epithelial cells are furthermore believed to be important
in maintenance of a healthy micro-environment, whiles is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
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Kleberg et al. BMC Gastroenterology 2012, 12:78 Page 2 of 12
http://www.biomedcentral.com/1471-230X/12/78dysfunction of these excretory mechanisms is suspected
to cause a cytotoxic and potentially oncogenic milieu
[6]. Special attention has been paid to members of the
large ATP-binding cassette family (ABC-transporters)
[2]. An association of these transporters to cancer is well
established with respect to response to anti-cancer treat-
ment and prognostics [4]. Studies on a possible connec-
tion to cancer development by other types of
transporters such as the organic anion transporting poly-
peptides (OATPs) are now being initiated as well [5,7-
10]. However, the function and build-up of the colonic
excretory system including its transporters are yet insuf-
ficiently characterized.
Recently, second messengers in form of cyclic nucleo-
tides (cNTs) such as cAMP and cGMP have turned out
as shared substrates for some OATP- and ABC-
transporters [11,12]. Both transporter families have
members characterized by substrate promiscuity and
overlap [13]. The importance of cellular import and ex-
port of cNTs is still debated, though gradually accepted
as a mean to regulate intracellular levels of these signal-
ing molecules [11,12]. cNT influx is thought to occur by
transporter OATP4C1, newly reported to influx cAMP
over the basolateral membrane of kidney tubule cells
and also present in the human colon [11,14]. Known
mediators of cNT-efflux, as ABCC4, ABCC5 and
ABCC8, are expressed in colonic tissue together with
other ABC-transporters as established by rt-qPCR
[15,16]. Meanwhile, it is unknown which transporters
are involved in the turnover of cNTs in colon epithelial
cells and which colonic transporters are involved in
functions possibly related to cancer progression and
prognostics [14].
It has become easy to assess transporter function and
secretion in in vitro human colon epithelium by means
of the mini-Ussing air suction (MUAS)-chamber tech-
nique [17]. And, since colonic secretion is induced by
cAMP, which is likely transported basolaterally to the in-
terior by presence of the OATP4C1-influxer, we have
taken advantage of this transfer to study the effect of ex-
ternally applied cNTs on the induction of colonic secre-
tion and possible excretion.
The overall aim of this study had two objectives. One
objective was to functionally characterize the excretory
system of human colon and to investigate whether
alterations or dysfunctions in this molecular excretory
system is associated with CRN and CRC pathogenesis.
The second objective was an initial characterization of
the turnover processes of second messenger cAMP,
related to transporters in human colonic mucosa.
We conclude that transporters as OATP1C1,
OATP4A1, OATP4C1 seem to be involved in the excre-
tory system of human colon. ABCC4 is also involved but
from an endoplasmic-Golgi complex location, whileOATP2B1 is indirectly related to the excretory system.
ABCC5 might be directly involved in the turnover of
intracellular cAMP. Colonic epithelium from CRN-
patients had lower transport or sensitivity to cyclic
nucleotides and an increased expression of two PGE2-
transporters, OATP2B1 and OATP4A1; however it is
premature to draw firm conclusions based on this latter
observation.
Methods
Study population and biopsy procedure
Patients, 50 years or older and referred to colonoscopy,
were enrolled in the study. Medical history was recorded
according to case notes. Patients with either a history of
or present colorectal neoplasia were included in the neo-
plasia group, whereas patient with no present or former
neoplasia were placed in the control group irrespective
of other extra-intestinal diagnoses. Patients were
excluded from the study in case of history of any kind of
chronic inflammatory condition of the intestine or if
they had recently been or were presently undergoing a
radiation and/or chemotherapy for CRN. A total of 19
patients were enrolled, with 11 subjects in the neoplasia
group and 8 subjects in the control group. There were
four women in each group and the mean age was
67 ± 13 yrs in the control group and 69 ± 4 yrs in the
neoplasia group.
Six biopsies from each patient were obtained during
endoscopy from macroscopically normal appearing mu-
cosa using standard biopsy forceps (Radial Jaw 3) from
Boston Scientific with an outside diameter of 2.2 mm.
The biopsies were obtained approximately 30 cm from
the anus and at least 10 cm from macroscopically abnor-
mal tissue on retraction of the endoscope. Biopsies were
immediately transferred to an iced, oxygenized bicarbon-
ate Ringer solution with the following composition (in
mM): Na+ (140), Cl- (117), K+ (3.8), PO4
- (2.0), Mg2+
(0.5), Ca2+ (1.0) and HCO3
- (25). pH was adjusted to 7.4
by gassing the media with 95% O2/5% CO2.
Ethics
The study protocol was approved by the Scientific Eth-
ical Committee of Copenhagen (KA 97161) and Freder-
iksberg Counties (KF01-232/03) and conducted in
accordance with the Helsinki declaration. All patients
participating gave written informed consent.
Chemicals
Theophylline, indomethacin, acetazolamide, NPPB, SITS,
rifamycin SV, cAMP and cGMP were purchased from
Sigma-Aldrich (Seelze, Germany). db-cAMP, db-cGMP
and OATP antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA), OATP1C1 (cat.
no.: sc-51350), OATP2B1 (cat. no.: sc-66561), OATP4A1
Kleberg et al. BMC Gastroenterology 2012, 12:78 Page 3 of 12
http://www.biomedcentral.com/1471-230X/12/78(cat. no.: sc-51169), OATP4C1 (cat. no.: sc-136775).
Bumetanide was received as a gift from Leo Pharmaceu-
ticals (Copenhagen, Denmark). ABC-antibodies were
obtained from LifeSpan Biosciences (Seattle, WA, USA),
ABCB1 (cat. no.: LS-A9403-50), ABCC3 (cat. no.: LS-
C16477-250), ABCC4 (cat. no.: LS-B4-50), and ABCC5
(cat. no.: LS-B2334-50). Oligo primers were obtained
from Tag Copenhagen (Copenhagen, Denmark). Normal
goat and rabbit serum was purchased from Dako
(Glostrup, Denmark). All other chemicals were of analyt-
ical grade.
Functional characterization in MUAS-chamber
Biopsies were mounted in MUAS-chambers as previ-
ously described [17]. Pretreatment of the biopsies was
performed 15 min mounting. Amiloride (100 μM, api-
cally) was added to inhibit ENaC-mediated sodium
transport. Theophylline (400 μM, apically and basolater-
ally) was added to dampen endogenous breakdown of
cNTs. Indomethacin (40 μM, basolaterally) was added to
inhibit endogenous synthesis of cNTs. Experiments were
conducted after additional 20 min equilibration. cAMP,
cGMP, dibutyryl-cAMP and dibutyryl-cGMP were used
as model substrates of OATP and ABC-transporters and
applied either luminally or basolaterally (500 μM). Each
experiment was terminated by basolateral addition (in
μM) of bumetanide (25), NPPB (500), SITS (1000), and
acetazolamide (250), alone or in combination. In a few
experiments after pretreatment, rifamycin SV (50–
100 μM) was added to either side of the tissue to test for
its inhibition of cNT influx.[18,19]. DMSO was the ve-
hicle for applying lipid soluble drugs and its final con-
centration always kept below 1 per mille in chambers. A
thorough discussion concerning the validity of measured
SCC and slope conductance by the MUAS-method is
presented earlier [17].
After completion of the study the biopsies were gently
dismounted and preserved in 4% paraformaldehyde for
subsequent histological assessment of tissue integrity.
Epithelium preservation on biopsies was scored on a
scale from 0 to 3, where 0 is overall intact epithelial sur-
face, 1: slightly damaged epithelium, 2: at least 1/3 intact
epithelium and 3: practically no intact epithelial surface.
RNA isolation
From each patient, one biopsy was frozen on dry ice and
saved at −80 °C for rt-qPCR studies. For RNA isolation,
biopsies were homogenized using a Polytron (PT 1600
E) for 2 min. RNA isolation was performed using a
NucleoSpinW RNA/Protein kit from Macherey-Nagel
(Düren, Germany). RNA concentration was determined
with NanoDropW ND-1000 from NanoDrop Technolo-
gies (Wilmington, DE, USA), and the purity assessed by
means of absorbance ratios (A260/A230 and A260/A280).Primer design
Rt-qPCR for eight transporter genes was performed on
biopsies from 6 patients in both groups using β-actin as
reference gene. The following eight transporters were
selected based on previous reports on presence in
human colonic mucosa: OATP1C1, OATP2B1,
OATP4A1, OATP4C1, ABCB1, ABCC3, ABCC4, and
ABCC5 [14]. Gene sequences were retrieved via www.
ensemble.org and the primers were designed using Pri-
mer 3 software. NetPrimer software was used to identify
and exclude primers with a tendency to dimer and/or
hairpin formation.
Selected primers were: β-actin (forward: ACCCAGCA-
CAATGAAGATCA, reverse: CGTCATACTCCTGCTT




(forward: TTCCTGATGACAGAACAGTGC, reverse: AC
AGCCGACTTTAAACCACAG), OATP4C1 (forward:
GGCTTTCTGCTTCACTACTGC, reverse: CATAACG
CTTCTCAACAGTGG), ABCB1 (forward: TGGATT-
CATCAGCTGCATTT, reverse: TGATGGAGTCATTGT
GGAGAA), ABCC3 (forward: TACTCTCTGCCCTCATC
TTGG, reverse: AAAACAGGCGGGAGAGAAA), ABC




cDNA synthesis was conducted using an iScript™ cDNA
Synthesis Kit from Bio-Rad (Copenhagen, Denmark)
according to manufactures instructions as previously
described [20].Rt-qPCR
For rt-qPCR, cDNA was amplified using a Fast SYBRW
Green Master Mix (Applied Biosystems). Samples were
run in four dilutions (0.05, 0.5, 5.0, and 10% cDNA v/v)
on 384 well plates in volumes of 10 μL and primer and
master mix concentrations of 0.6 μM and 50%v/v, re-
spectively. All samples were run in triplicate with β-
actin on all plates. Amplification was performed using a
7900HT Fast Real-Time PCR System from Applied Bio-
systems (Foster City, CA, USA) in accordance with the
supplier’s manual. Standard and dissociation curves con-
firmed acceptable amplification efficiencies and specifici-
ties of the primer sets. The expression profiles were
calculated using the deltaCT-method in which the amp-
lification calculation is adjusted for primer-set efficien-
cies [21]. Results were analyzed using adjuvant SDS 2.3
software. Results are based on the 10% cDNA dilution.
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One colon biopsy from each patient was put aside in 4%
neutral buffered formaldehyde after the endoscopic pro-
cedure. Biopsies were subsequently embedded in paraffin
and cut in 10 μm thin slices. Immunohistochemical
localization of transporters was performed on biopsies
from two patients in each group. The sections were
deparaffinated and rehydrated, followed by heat treat-
ment in a microwave oven in order to unmask epitopes.
The sections were blocked with a 2% bovine serum albu-
min solution for 10 minutes, to rule out unspecific anti-
body adhesion, followed by incubation with a primary
antibody at 4 C overnight in the following concentra-
tions: OATP1C1 (1:100), OATP2B1 (1:100), OATP4A1
(1:100), OATP4C1 (1:400), ABCB1 (1:400), ABCC3
(1:400), ABCC4 (1:400), and ABCC5 (1:400). Biotiony-
lated secondary antibodies were detected using a
streptavidin-bioptin-complex coupled to horse radish
peroxidase and a diaminobenzidin stain, color-enhanced
with CuSO4. Finally, the biopsies were periodic acid-
Shiff-hematoxylin stained. For negative controls primary
antibody was replaced by either normal goat (Dako
X0902) or rabbit (Dako X0907) serum (1:100). Images
were recorded using an Ortoplan microscope (Wetzlar,
Germany) fitted with an Evolution MP camera (Silver-
spring, MD, USA) and analysis was performed using
Image-Pro 5.0 software.
Statistical analysis
Hypothesis testing was done by unpaired student’s t-test
or Mann–Whitney rank sum test. P-values below 0.05
were considered significant. All SCC-signals obtained
were included with the same weight regardless of the
number of biopsies from each patient. This procedure
was chosen in order to reduce the importance of outliers
in the single patient. All statistics were performed using
SigmaPlot 11.0 software.
Results
Functional characterization of transport
From each patient three to four biopsies were success-
fully mounted. Slope conductance ranged between 30
and 60 mScm-2 during the observation period and with
a stable baseline SCC (basal SCC). Examples of SCC
responses to pretreatment and to cyclic nucleotide ex-
posure are shown in Figure 1. When basolaterally ap-
plied, extracellular cAMP, cGMP, and db-cGMP gave
rise to 10–20 μAcm-2 secretory signals, implying a baso-
lateral influx mechanism of cNTs into cells. The same
was observed for basolateral db-cAMP, but this com-
pound lead to a 5–10 fold larger response. Figures 1B-E
show representative responses to serosally applied cNTs.
The means of induced currents for all 4 compounds in
each patient group are presented in Figure 2A. Contrary,apical addition of the four nucleotides had no effect on
SCC. This is shown for cAMP and db-cAMP in
Figure 1A, indicating db-cAMP as a non-permeable
analogue in our experimental setting and implying a
transport mechanism at the basolateral membrane.
As appears from Figure 2A, no significant differences
in size of induced current were identified between pa-
tient groups for cAMP, cGMP or db-cGMP. However,
for db-cAMP which induced the largest signal, the in-
crease in SCC was significantly lower in biopsies from
patients with neoplasia (p = 0.024). The lower response
to transported db-cAMP in CRN patients could be due
to altered transport function and/or altered expression
or activity of responsible transporters. Alternatively, a
mechanism downstream in the cAMP-activated pathway
might be altered, see Discussion.
The induced SCC-signals were subsequently to a large
extent inhibitable with bumetanide (Figure 1A) implying
that mainly a Cl--secretion was responsible for the cNT-
induced increase in SCC. Addition of acetazolamide fur-
ther decreased the SCC (Figure 1A), indicating that
intracellular bicarbonate was contributing to the
observed secretory response. The inhibitory effects of
bumetanide and acetazolamide are summarized in
Figure 2C.
Induced SCC unaffected by bumetanide and acetazola-
mide accounted for up to 25% and in order to identify
the mechanisms behind this current, inhibitors of co-
transporters AE1/2 and NBC were applied separately.
No effect was observed with addition of SITS, but NPPB
caused a large decrease in SCC, resulting in a complete
inhibition of the remaining db-cAMP-induced current
(data not shown). This suggests that a sodium coupled
bicarbonate transport of exogeneous bicarbonate avail-
able in the Ringer solution is probably also responsible
for the least 25% of the cNT-induced SCC.
Differential transporter expression in biopsies
All eight included transporters were detected in biopsies
by rt-qPCR. Relative expressions of OATP- transporters
are presented in Figure 3. Only OATP2B1 and
OATP4A1 showed significantly altered expressions in
patients with neoplasia compared to controls. Both were
expressed significantly higher in biopsies from neoplasia
patients (p = 0.017 and 0.013, respectively).
Relative expressions of ABC-transporters are shown in
Figure 4. ABCB1 had the highest expression level.
ABCC3 and ABCC5 were expressed to nearly the same
extent, whereas ABCC4 was sparsely expressed com-
pared to the other ABC-transporters. None of the trans-
porters positively demonstrated to transport cAMP and
cGMP [11,12,22] were over- or under-expressed between
patient groups as could be expected from functional
studies. This could imply an altered activity in
Figure 1 Example of short circuit current data from a MUAS-chamber. A: Typical responses from compounds applied apically and/or
basolaterally. a: amiloride, b: theophylline, c: indomethacin, e: cAMP (basolateral), g: db-cAMP (basolateral), h: bumetanide, and i: acetazolamide.
d: and f: apically applied cAMP and db-cAMP, respectively. B-E: Typical examples of induced SCC by the four model compounds.
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ther than expression being responsible for the functional
difference observed in MUAS chamber studies, Figure 2.
Transporter localization
Figure 5 shows images of biopsy specimens treated with
OATP antibodies. OATP1C1 was detected at the baso-
lateral membrane of goblet cells, whereas no staining
was observed in columnar epithelial cells, Figure 5A.
The OATP1C1 transporter is a known hormone and
xenobiotics transporter with high affinity for tyroxine
[16]. Its basal location in goblet cells therefore indicates
a secretory function here for hormones and xenobiotics.
OATP2B1 was exclusively detected in endocrine cells
dispersed between columnar epithelial cells and gobletcells, Figure 5B. This indicates a regulator function ra-
ther than a direct excretory function. OATP4A1 was
detected at the basolateral membrane of columnar epi-
thelial cells, indicating a putative excretory function of
this transporter, Figure 5C.
The immuno-reaction for OATP4C1, although weak,
was located to the basolateral aspect of goblet and col-
umnar epithelial cells, Figure 5D. This localization is
similar to the position in the kidney tubule. As this
transporter carries cNTs, it may account for a low cap-
acity inward flux of externally applied cNTs as measured
indirectly in this study, Figures 1 and 2 [11].
The subcellular localizations of the ABC-transporters
are presented in Figure 6. ABCC3 was found to be
located basolaterally in both columnar epithelial cells
Figure 2 Mean short circuit signals. A: Induced SCC by 500 mM of the 4 cNTs presented as mean± SEM. Control patients: cAMP (N= 7, n = 10),
cGMP (N= 5, n = 7), db-cAMP (N= 7, n = 14), db-cGMP (N= 7, n = 12). Neoplasia patients: cAMP (N = 7, n = 12), cGMP (N = 10, n = 20), db-cAMP
(N= 10, n = 32), db-cGMP (N= 4, n = 7). B: Responses to application of theophylline and indomethacin. Bars represent Mean± SEM. Control
patients: Theophylline (N= 8, n = 25), indomethacine (N= 8, n = 27). Neoplasia patients: Theophylline (N= 11, n = 37), indomethacine (N = 11,
n = 41). C: Responses to application of bumetanide and acetazolamide. Bars represent Mean± SEM. Control patients: Bumetanide (N = 6, n = 12),
acetazolamide (N= 5, n = 11). Neoplasia patients: Bumetanide (N= 9, n = 24), acetazolamide (N = 9, n = 25). N = number of patients and n= number
of biopsies. * indicates a statistical significant difference between the two groups.
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[23]. Interestingly, ABCC4 was not detected in the
plasma membrane of epithelial cells, but in the basolat-
eral aspect and perinuclear membranes of goblet cells,
Figure 6B. In other studies it has been found in the ap-
ical membrane of tubular cells in the kidney and basolat-
eral membrane of the liver and small intestine [23].
ABCC5 was located at the basolateral membrane of col-
umnar epithelial cells suggesting that this transporter
very well could be implicated in local excretion of xeno-
biotics as well as occupying a role in intracellular levels
of cAMP and cGMP. Localization of ABCB1 could not
be determined, as the chosen antibody did not complex
with possible epitopes (4 experiments, data not shown),
but its localization is well described and confined to the
apical membrane of human colonic epithelial cells
[24,25].
No differences in localization between the two groups
of patients were observed in biopsies subjected to
immunohistochemistry.Studies with rifamycin
Rifamycin SV was added in an attempt to inhibit the
effects of db-cAMP, as rifamycin SV is known to inhibit
several of the OATP transporters with an IC50 around
1 μM [18,19]. Meanwhile, rifamycin had no effect on
basal or db-cAMP-induced SCC, data not shown. The
employed concentration of rifamycin gave a clear yel-
low coloring of the media, and since the coloring was
not transferred to the other half chamber during at
least two hours of experimentation, we conclude that
the media on either side of the tissue are fairly well
separated.
Tissue integrity
A total of 76 biopsies from 19 patients were included in
the study and the overall structure of the biopsies was
well kept, as approximately 80% were intact or only
slightly damaged. Scoring of biopsies after end of experi-
ment in MUAS-chambers was as follows: 0 (17), 1 (45),
2 (9), 3 (3). Data from biopsies assigned to category 3
Figure 3 OATP expression. Expression levels of the OATPs relative to β-actin based on single biopsies from 6 patients in each group. * indicates
a statistical significant difference (p< 0.05) between the two groups. Data are presented as means ± SEM.
Kleberg et al. BMC Gastroenterology 2012, 12:78 Page 7 of 12
http://www.biomedcentral.com/1471-230X/12/78were excluded from the statistics. Two biopsies were
pinched deeper and the surface epithelium could not be
assessed. However, the signals achieved from these biop-
sies fell within the range of the data and they were
included in the statistics.Figure 4 ABC expression. Expression levels of the ABC-transporters relativ
Data are presented as means ± SEM.Discussion
The present study was initiated to further elucidate two
aspects of the normal function of human colon epithe-
lium, viz., colon’s epithelial excretory system of toxic and
waste molecules and colon’s use and turnover of seconde to β-actin based on single biopsies from 6 patients in each group.
Figure 5 OATP-transporter localization. A: OATP1C1, B: OATP2B1, C: OATP4A1, D: OATP4C1. White arrows indicate the location at the bottom
of the goblet cells, black arrows staining of endocrine cells and yellow arrows basolateral staining of epithelial cells.
Figure 6 ABC-transporter localization. A: ABCC3, B: ABCC4, and C: ABCC5. Yellow arrows indicate the basolateral staining of ABCC3 in
coloumnar epithelial cells and goblet cells. White arrows indicate the localization of ABCC4 in basolateral and perinuclear membranes of goblet
cells, and black arrows indicate the basolateral staining of ABCC5 in columnar epithelial cells. D-E: Negative control images of staining with
secondary antibody from goat (D) and rabbit (E). No immunohistochemical coloring was obtained for the ABCB1 transporter.
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these functions are altered in the neoplastic condition of
the colonic tissue.
The excretory system of human colon epithelium
Recently, more detailed understanding has emerged of
how the body rids itself of waste metabolites and toxic
products. Indeed, three epithelia are in focus: cells of the
bile canaliculus, the kidney tubule, and the colon mu-
cosa [13,15,23,26]. Of these three epithelia, the colonic
excretory system is the least studied, in spite it is
involved in the final steps for excretory processes of the
gastrointestinal tract [14,26]. We therefore decided to
characterize the expression and localization of selected
ABC- and OATP transporters assumed to be involved in
the excretory mechanisms as well as in the handling of
cAMP in human colon. The analysis of expression and
localization of transporters are shown in Figures 3, 4, 5
and 6 and a summary of the results with a model of the
colonic excretory system is shown in Figure 7A. The
localization of transporters needs affirmation, e.g. by a
double labeling technique. For the regulated turnover of
cAMP in human colon, a model is presented in
Figure 7B.
Probing the excretory system with cNTs
We have studied effects of externally applied cyclic
nucleotides, cAMP, cGMP, db-cAMP and db-cGMP, on
induction of some aspects of the excretory process in bi-
opsies of human colon mucosa. The results are shown
in Figures 1 and 2 and indicate that cNTs are carried by
specific transporters across the basolateral membrane of
epithelial cells, while the luminal cell membrane lacks
these transporters as no anion secretory response can be
induced when applying the cNTs in the luminal media,
Figure 1A.
Since the blood side concentration of cNTs, used to
obtain a sizable response was rather high (sub-millimo-
lar range), compared to the cNT concentration (around
1 μM) known to be effective when present in the cyto-
plasm [27], this indicates that the transport of cNTs is of
a limited capacity as the induction of a secretory re-
sponse is a balance between influx and elimination of
cAMP. The elimination of intracellular cAMP is effectu-
ated by residual phosphodiesterase activity and active ex-
port, see below. A likely candidate for the influx
transport of cNTs is the influx digoxin transporter
OATP4C1 known to also transport cNTs [11] and
regarded as a kidney specific transporter implicated in
the removal of uremic toxins, waste products, and drugs
[28]. The necessary high cNT concentration needed to
elicit an effect also seems to exclude an interaction with
a possible cNT receptor on colonic epithelial cells simi-
lar to the cAMP induction of spore formation for theslime mould Dictoystelium discoideum at an external
cAMP receptor with an EC50 around 1 μM [29].
Moreover, when applied externally, db-cAMP is sev-
eral fold more efficacious in inducing a secretory re-
sponse than the other three employed cNTs, including
cAMP, as can be seen from the results in Figure 2A.
One likely explanation for this observation is that a
basolateral influx transporter is more selective for db-
cAMP with higher affinity and/or efficacy. Other pos-
sible explanations are that the sensitivity of cytoplasmic
cAMP receptors, such as the regulatory unit of protein
kinase A, is higher to db-cAMP than to cAMP itself or
alternatively that the breakdown to non-cyclic nucleotide
of cyclic nucloetides by phophodiesterases in the cyto-
plasm is less efficient for db-cAMP than for the other
cNTs; as demonstrated several years ago in cell cultures
[30]. Yet, another possibility is a less efficient active ex-
port of db-cAMP by ABCC5 as compared to for in-
stance cAMP, see next section.
It may be noted, that for isolated hen colon compared
to human colon, the ratio effect on SCC by cAMP and
db-cAMP is reversed. By similar external additions to
the basolateral side of hen colon, cAMP increases the
SCC (134 +/− 11 μA,cm-2, n = 74) 6 fold above that for
db-cAMP (Bindslev, unpublished data).
Model for colonic handling of cAMP and other cyclic
nucleotides
Based on results obtained in this study with expression
and localization of transporters in the human colonic
mucosa, Figures 3, 4, 5 and 6, and other evidence in the
literature [22], we propose a model for and give a discus-
sion of the handling of cAMP in human colonic epithe-
lium as shown in Figure 7B in relation to production,
compartmentalization, degradation and active export of
this second messenger; and possible relevance to devel-
opment of colorectal cancer [17,31].
One of the regulatory pathways for synthesis of cAMP
is the step starting with COX enzymes producing prosta-
glandins of the E series (e.g., PGE2) which activate EP
subtype specific receptors (especially the EP4 subtype re-
ceptor in human colon) [17], transducing the signal
through Gαs proteins to various isoforms of the adenyl-
ate cyclase enzyme, AC [32,33]. cAMP is confined to a
submembraneous compartment just under the basolat-
eral membrane from where it is eliminated by either of
two pathways [12,34]. One down-regulatory pathway is
the classical degradation of cAMP by cAMP-specific
phosphodiesterases, PDEs. For the anion secretory
process in human colon epithelium, the PDEIII subtype
seems to be most important (unpublished data by dr. G.
Majgaard). db-cAMP is known to be more resistant to
PDE degradation in cell systems than cAMP and this
could explain its observed higher efficacy [30]. Another
Figure 7 Model of human colon secretory and cAMP turnover systems. A: Schematic presentation of the secretory system of the colon as
revealed by this study. The subcellular location of ABCB1 was not determined in this study but has been localized to the apical membrane by
others. * Indicates significantly increased expression in CRN patients. B: Schematic presentation of the cAMP-turnover system in a colonic
epithelial cell. AC: adenylate cyclase. PDE: phosphodiesterase.
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of db-cAMP in the two patient groups could hence be
due to an increase in PDE activity or lowered sensitivity
of PKA to db-cAMP in the CRN group.
Another well-described down-regulatory pathway for
cAMP is via export pumps at the basolateral membrane
from the nearby cAMP compartment, Figure 7B [34,35].
The most likely export pump for cAMP in the human
colon epithelium is the ABCC5 transporter as it is loca-
lized to the basolateral cell membrane, Figure 6C. Usu-
ally the ABCC4 transporter is considered the most
potent cAMP export pump among the known cAMP
exporters, ABCC4, ABCC5, and ABCC8 [22]. However,
the ABCC4 transporters do not seem to be located in
the basolateral cell membrane of epithelial columnar
cells but rather in basolateral membrane as well asperinuclear and secretory vesicle membranes of goblet
cells, Figure 6B. The function of this export pump here
is unknown so far, but may be involved in an export of
antimicrobial proteins similar to defensins [36] coming
from colon crypts cells, CD24(+); residing between Lgr5
stem cells representing Paneth cell equivalents in colon
[37].
Influx of cNTs across the epithelial basal membrane
can explain the observed induction of ion secretion by
externally applied cNTs. cNT influx we ascribed to
OATP4C1, which is a known cAMP influxer [11] and
expressed in human colonic tissue, Figure 3D [14], at
the basolateral membrane of colonic epithelial and gob-
let cells, although only weakly visible, Figure 5 D. Thus,
a firm proof of OATP4C1’s localization and function
must await further studies.
Kleberg et al. BMC Gastroenterology 2012, 12:78 Page 11 of 12
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expression in the colonic excretory system
As shown in Figure 2, the induction of a colonic
secretory response by db-cAMP was significantly lower
in CRN affected patients compared to non-CRN
patients. None of the studied colonic transporters
known to be involved in influx and/or efflux of cNTs, i.
e., OATP4C1, ABCC4 and ABCC5, were significantly
altered between CRN and non-CRN patients, Figures 3
and 4. This points to a lower sensitivity to db-cAMP in
the PKA pathway of colonic mucosa from CRN patients,
rather than an altered membrane transport rate between
the two patient groups, e.g., a reduced influx or an aug-
mented efflux rate for the CRN colon, Figure 7B.Expression and location of other transporters in relation to
CRN
The significant increase in PGE2- influx transporters
OATP2B1 and OATP4A1 in colon biopsies from CRN-
patients, Figure 3, may indicate that these transporters
are somehow involved in a mediated excretory function,
up-regulated with neoplasia. However, our negative
results with rifamycin which is a rather potent inhibitor
of these two OATP-transporters seem to indicate that
neither OATP2B1 nor OATP4A1 are involved in the
basolateral cNT transport. Furthermore, if OATP4A1
transported cNTs into colonic mucosal cells, this does
not fit with its increased expression in non-CRN and a
lower transfer in colon from CRN affected patients.COX enzymes, NSAID and PGE2 transporters in human
colon
It has been known since the 1960s that drugs of the
NSAID-type in doses as low as 10–30 μM can amelior-
ate the course of colorectal cancer [31,38]. In view of
NSAIDs as classical inhibitors of COX enzymes, their ef-
fect is also to lower production of prostaglandins, in
human colon, as for instance PGE2 and PGF2-alfa and
thereby the content of second messengers as cAMP and
other cyclic nucleotides, cNTs, in epithelial cells [39].
The export and import of PGE2 in normal, native co-
lonic mucosa has so far been assumed via transporters
as ABCC4 and OATP2A1 (prostaglandin transporters)
[12], presumably also in the basolateral epithelial cell
membrane. The basolateral PGE2-export should maybe
rather be ascribed to ABCC5 as found basolaterally in
this study and the import also possibly related to a new
PGE2 OAT-transporter found in colonic tissue [40]. Fur-
thermore, OATP2B1 and OATP4A1 are both up-
regulated in CRN-patients and known to transport PGE2
[15,16,41]. Therefore, studies combining effects of all
PGE2 transporters, their expression and localization in
normal human colonic mucosa are warranted.Conclusions
The SCC induced by db-cAMP in CRN-patients is signifi-
cantly lower than in non-CRN patients. This implies a
correlation between CRN and lower transport of or sensi-
tivity to db-cAMP. The study has ascertained ABCC5 and
excluded ABCC4 as a cNT efflux pump in basolateral
membranes of human colonic epithelial cells. ABCC4 is
rather located to the basolateral and perinuclear mem-
branes of goblet cells. OATP4C1 is a likely influx trans-
porter of cNTs in human colon epithelial cells, but this
needs additional investigations to be confirmed. Further-
more, there is a higher expression of OATP4A1 and
OATP2B1 (both influxers of PGE2) in colon from CRN-
patient compared to non-CRN-patients. How this altered
expression correlates with an observed lower secretion
induced by db-cAMP in CRN is unresolved, but may indi-
cate a CRN-induced removal of known augmented co-
lonic content of prostaglandins.
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